Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07397416

Impact of Implementing a Rapid PCR-based Algorithm for Carbapenemase-producing Enterobacterales (CPE) and Infection Control Bundle in a Tertiary Hospital

Purpose:

Carbapenemase-producing Enterobacterales (CPE) are a growing cause of healthcare-associated infections, linked to high morbidity, mortality, and cost. Current screening methods rely mainly on culture, which can take up to 48 hours and delay infection control actions.

This study aims to evaluate the real-life impact of implementing a rapid PCR-based algorithm for CPE detection compared with the standard culture-based protocol, focusing on time differences in isolation and de-isolation decisions in hospitalized patients.

Design:

A quasi-experimental, before-and-after, retrospective study conducted at Hospital Italiano de Buenos Aires (HIBA).

Primary Outcome:

Time (in hours) between rectal swab request and change in isolation status (application or removal of isolation label) before and after PCR implementation.

Population:

Adult patients (≥18 years) admitted between October 2023-April 2024 (pre-intervention) and October 2024-April 2025 (post-intervention), who had contact isolation initiated or discontinued based on CPE surveillance results.

Rationale:

The introduction of rapid molecular testing could reduce operational delays and unnecessary isolation days, optimizing resource use in a setting with high CPE endemicity.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

About this study

Background:

Carbapenemase-producing Enterobacterales (CPE) are critical-priority pathogens associated with increased morbidity, mortality, and healthcare costs. Screening and isolation are recommended infection control measures, yet delays inherent to culture-based methods can hinder timely decision-making and overuse limited isolation rooms.

Objective:

To compare the time to initiation and discontinuation of contact isolation-from swab request to result availability and isolation status update-before and after implementing a rapid PCR-based diagnostic protocol for CPE identification.

Design and Setting:

Retrospective, quasi-experimental before-after study at the Hospital Italiano de Buenos Aires, Argentina. The pre-intervention period covers October 1, 2023-April 30, 2024; the post-intervention period covers October 1, 2024-April 30, 2025.

Intervention:

Incorporation of real-time PCR testing (BD MAX™ System) for CPE genes (bla_KPC, bla_NDM, bla_VIM/IMP, bla_OXA-48-like) into the existing CPE surveillance and isolation reevaluation workflow. The infection control team coordinates sample requests and response actions.

Primary Outcomes:

Time difference (in hours) from surveillance swab request to isolation implementation.

Time difference (in hours) from surveillance swab request to isolation discontinuation.

Secondary Outcomes:

Time differences stratified by weekday versus weekend.

Time differences according to sampling time (08:00-16:00 vs 16:00-08:00).

Time differences according to immunosuppression status.

Time differences in ICU versus general ward settings.

Data Collection:

Four timestamps will be extracted from the electronic health record (EHR): swab request, laboratory check-in, final laboratory result, and change in isolation logo. These will allow computation of operational intervals (request → action), collection delay, processing delay, and action delay.

Statistical Analysis:

Continuous variables will be summarized as medians and interquartile ranges. Median time differences between pre- and post-intervention periods will be compared using mixed-effects linear regression adjusted for immunosuppression, ICU admission, day of the week, and public holidays. Analyses will be conducted using Stata v16.

Ethical Considerations:

The study is retrospective and minimal-risk, involving only secondary use of clinical data. It has been submitted to the CEPI (Comité de Ética de Protocolos de Investigación), Hospital Italiano de Buenos Aires (PRIISA 15728), with waiver of informed consent under CIOMS 2019 Guideline 10.

Expected Impact:

By quantifying real-time process improvements after PCR implementation, this study will provide evidence on diagnostic turnaround times and operational efficiency in infection control practices.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult patients aged ≥18 years
  • Patients screened for carbapenemase-producing Enterobacterales (CPE) carriage by perianal swab within the first 5 days of hospital admission
  • Patients newly identified as CPE-colonized, leading to initiation of contact isolation
  • Patients found to be decolonized, leading to discontinuation of contact isolation
  • Patients with indication for active surveillance at hospital admission:
  • Transfer from another healthcare facility
  • Hospitalization in another healthcare center within the previous month
  • Patients undergoing active surveillance during hospitalization:
  • First surveillance swab in high-risk neutropenic patients (HAR flag)
  • First surveillance swab in immunosuppressed units, such as hematopoietic stem-cell transplant wards
  • Patients evaluated for discontinuation of contact precautions who meet all of the following:
  • Prior CPE-positive surveillance sample
  • At least 3 months since the last positive result and last hospitalization
  • No systemic antibiotic exposure during that period

Exclusion criteria

  • Lost samples
  • Insufficient samples
  • Invalid laboratory test results requiring repeat sampling

Treatment and study plan

Rapid PCR-based algorithm for CPE detection

Diagnostic Test

Implementation of a rapid real-time PCR-based diagnostic algorithm for the detection of carbapenemase-producing Enterobacterales (CPE) integrated into the institutional infection control workflow. The BD MAX™ System detects bla_KPC, bla_NDM, bla_VIM/IMP, and bla_OXA-48-like genes from rectal swabs. The infection control team manages the process from sample request to result-based isolation decision. The intervention began on November 6, 2024, upon availability of PCR supplies and reagents.

Other names: Rapid molecular diagnostic algorithm for CPE; BD MAX CPE PCR workflow

Primary outcomes

  1. Time from surveillance swab request to isolation implementation or discontinuation (hours)

    Time frame: From the date and time of electronic request for perianal swab collection until the date and time of isolation status update in the EHR, assessed up to 168 hours (7 days).

    Primary Outcome Measure

    • Operational time from surveillance swab request to isolation status change (hours)

    Description:

    Time elapsed between the electronic request for perianal surveillance swab (clinical suspicion) and the implementation or discontinuation of the carbapenemase-producing Enterobacterales (EPC) isolation logo in the electronic health record (EHR).

    Unit of Measure: Hours

Secondary outcomes

  1. Sample collection delay (hours)

    Time frame: From the date and time of electronic request for perianal swab collection until laboratory check-in of the sample, assessed up to 72 hours.

    Description:

    Time elapsed between the electronic request for perianal surveillance swab and laboratory check-in of the sample.

    Unit of Measure: Hours

  2. Laboratory processing delay (hours)

    Time frame: From the date and time of laboratory check-in until the date and time of final laboratory result, assessed up to 96 hours.

    Time elapsed between laboratory check-in of the perianal swab sample and availability of the final laboratory result.

    Unit of Measure: Hours

  3. Action delay after laboratory result (hours)

    Time frame: From the date and time of final laboratory result until the date and time of isolation status update in the EHR, assessed up to 72 hours.

    Time elapsed between availability of the final laboratory result and update of the EPC isolation status (logo) in the electronic health record.

    Unit of Measure: Hours

Study contacts

Contact information is provided by the study sponsor or research team.

Emilio Felipe Huaier Arriazu, MD

CONTACT

[email protected]

+549 011 49590200 ext. 8165 / 9542

Sponsors and collaborators

Lead sponsor

Hospital Italiano de Buenos Aires

Other

Registry information

Official study title

Intervention in the CPE Surveillance Algorithm and Isolation Re-evaluation With the Addition of PCR vs. Culture-based Protocol: Real-life Time Differences

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Feb 9, 2026
Registry last updated
Feb 9, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.